๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Phase I trial of 5-fluorouracil, leucovorin, and cisplatin in combination

โœ Scribed by Peter J. O'Dwyer; Mark J. Cornfeld; Ruth Peter; Robert L. Comis

Publisher
Springer
Year
1990
Tongue
English
Weight
492 KB
Volume
27
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Dual modulation of 5-fluorouracil using
Dual modulation of 5-fluorouracil using leucovorin and hydroxyurea. A phase I trial
โœ J. Lokich; N. Anderson; M. Bern; F. Coco; T. Zipoli; C. Moore; L. Gonsalves ๐Ÿ“‚ Article ๐Ÿ“… 1991 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 318 KB ๐Ÿ‘ 2 views

Oral hydroxyurea (HU) was added to a regimen of 5-fluorouracil(5-FU) plus leucovorin (LCV) administered as a continuous 24-hour infusion for 14 days. A previous report of the 5-FU plus LCV infusion established optimal dosages of 200 mg/mz/d and 5 mg/mz/d, respectively, for each agent. Oral HU was ad

A phase II trial of methotrexate, cispla
A phase II trial of methotrexate, cisplatin, 5-fluorouracil, and leucovorin in the treatment of invasive and metastatic urothelial carcinoma
โœ William K. Oh; Judith Manola; Jerome P. Richie; Kevin R. Loughlin; Philip W. Kan ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 78 KB ๐Ÿ‘ 2 views

The current treatment of advanced urothelial carcinoma generates high response rates but is associated with poor overall survival. The current study evaluated the efficacy and toxicity of a new combination of active drugs in the treatment of urothelial carcinoma. ## METHODS. Twenty-four patients